MedAssets multiple poised to expand several times, says Sterne Agee Sterne Agee expects MedAssets to benefit from mounting margin pressure on hospitals, and the firm thinks the stock is "drastically undervalued" compared with its peers. It keeps a $30 price target and Buy rating on the stock.
Healthways, MedAssets partner in new five-year agreement Healthways (HWAY) has partnered with MedAssets (MDAS) to expand patient access to the Dr. Dean Ornish Program for Reversing Heart Disease. Under the five-year agreement, Healthways has contracted with MedAssets as its sales partner to accelerate deployment of the Ornish Reversal Program to hospitals, health systems and physician organizations. The Ornish Reversal Program is the most scientifically proven platform in lifestyle medicine for treating and reversing heart disease and other chronic conditions.